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Abstract: 
Arterial stiffness (AS) is a risk factor which coexist in high-risk populations 
including peripheral arterial disease (PAD). However, the prognostic impact 
of arterial stiffness in PAD remains to be defined. We investigated whether 
aortic Pulse Wave Velocity (aPWV) and Augmentation index normalized to 
75 beats/min (Aix @75HR) predict total mortality (all-cause and 
cardiovascular mortality) in patients with PAD. In 231 PAD with ABI ≤0.9 
at rest or with a positive Treadmill test performed on the borderline group 
(ABI=0.91-0.99) and 167 No-PAD (ABI ≥ 0.91<1.3) patients aPWV and Aix 
@75HR were evaluated using arterial tonometry and ABI were obtained 
using an 8-MHz Doppler probe. Total mortality rates in relation to ABI, 
aPWV and Aix@75HR were analyzed using Cox regression model. During a 
mean follow-up of 5.4±2 years 39 (16.9%) deaths occurred in PAD 
patients and 8 (4.8%) in those No-PAD. In the PAD group, the aPWV was 
associated with increased risk for total mortality (HR=1.14, 95% CI, 1.03-
1.26; p=0.016) independent of cardiovascular risk factors and CAD history. 
In conclusion, in PAD patients aPWV is also an indicator of total mortality 
that could be useful for risk stratification. 
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Arterial stiffness (AS) is a risk factor which coexist in high-risk populations including peripheral 
arterial disease (PAD). However, the prognostic impact of arterial stiffness in PAD remains to be 
defined. We investigated whether aortic Pulse Wave Velocity (aPWV) and Augmentation index 
normalized to 75 beats/min (Aix @75HR) predict total mortality (all-cause and cardiovascular 
mortality) in patients with PAD. In 231 PAD with ABI ≤0.9 at rest or with a positive Treadmill test 
performed on the borderline group (ABI=0.91-0.99) and 167 No-PAD (ABI ≥ 0.91<1.3) patients 
aPWV and Aix @75HR were evaluated using arterial tonometry and ABI were obtained using an 8-
MHz Doppler probe. Total mortality rates in relation to ABI, aPWV and Aix@75HR were analyzed 
using Cox regression model. During a mean follow-up of 5.4±2 years 39 (16.9%) deaths occurred in 
PAD patients and 8 (4.8%) in those No-PAD. In the PAD group, the aPWV was associated with 
increased risk for total mortality (HR=1.14, 95% CI, 1.03-1.26; p=0.016) independent of 
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cardiovascular risk factors and CAD history. In conclusion, in PAD patients aPWV is also an 
indicator of total mortality that could be useful for risk stratification. 
 
INTRODUCTION 
 
Peripheral arterial disease (PAD) is a cardiovascular disease highly prevalent in the elderly and in 
individuals with conventional cardiovascular risk factors (diabetes type 2, smoking history and 
hypertension).
 1
 The Ankle-brachial index (ABI) represents the primary noninvasive screening test 
for the diagnosis of PAD.
 2
 The ABI (≤0.9) is also an indicator of generalised atherosclerosis, as it 
has been associated with higher rates of concomitant coronary and cerebrovascular disease.
 3
 PAD 
patients with and without leg ischaemic symptoms have a three-fold increase in risk of myocardial 
infarction, stroke and all-cause and cardiovascular mortality compared to those without PAD.
 4-6
 
The increase in PAD-associated mortality may be mediated, through generalized atherosclerotic 
disease
 7
 that directly contributes to the development of arterial stiffness.
 8-11
 To our knowledge 
however, the impact of arterial stiffness on mortality remains to be demonstrated.
 12
 The aim of our 
study was to investigate whether aortic Pulse Wave Velocity (aPWV) and Augmentation index, 
normalized to 75 beats/min (Aix@75HR), predict total mortality (all-cause and cardiovascular 
mortality) in patients with PAD beyond traditional risk factors and coronary artery disease (CAD) 
history.  
 
METHODS 
 
Study Population  
 
A total of 722 subjects referred to the Angiology Unit, Research Center on Vascular Diseases, 
University of Milan L. Sacco Hospital were evaluated for non-invasive vascular tests: the Pulse 
Wave Analysis (PWA), was used to measure the Augmentation index, normalized to 75 beats /min 
(Aix@75HR), and aortic Pulse Wave Velocity (aPWV) to evaluate aortic stiffness. The Ankle-
brachial index (ABI) at rest was performed to diagnose PAD (ABI ≤0,90) at rest or with a positive 
Treadmill test performed on the borderline group (ABI=0.91-0.99).
 2
 We excluded patients with 
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known cancer, recent myocardial infarction and or stroke, (during the past 6 months), critical limb 
ischemia (CLI) and subjects with high ABI (≥1,3) that suggested poorly compressible, calcified 
arteries and in those without palpable femoral pulses, that indicated the presence of bilateral iliac 
disease which could cause inaccurate aPWV
 
measurements.
13
 Patients with cardiac dysrhythmias, 
such as atrial fibrillation, pacemakers and frequent extra systole were also excluded. The final study 
group included a total of 398 subjects age range (40-95 years), divided into 2 groups: the first was 
composed of 231 patients with PAD (ABI ≤0.9) and the second of 167 No-PAD (ABI ≥ 0.91 ≤1.3). 
All participants had been informed about the study protocol and gave their informed consent to 
participate in the study. Participants were followed up between July 2008 and July 2017. 
 
Risk factors PAD CAD and CVD definitions 
 
For data collection, history was taken and medical records were reviewed. Traditional 
cardiovascular risk factors were assessed: age, gender, smoking history, hypertension, diabetes type 
2, dyslipidemia. Arterial hypertension was defined as systolic blood pressure (SBP) ≥140 mm Hg or 
diastolic blood pressure (DBP) ≥90 mm Hg at the time of the visit (mean of two readings) or history 
of hypertension or use of antihypertensive medication (diuretics, α-blockers, β-blockers, 
Angiotensin-converting enzyme inhibitors, AT2-blockers or Ca-antagonists). Type 2 diabetes 
mellitus was defined as a fasting blood glucose ≥126 mg/dL or history of diabetes or of use of 
diabetes medication (insulin or oral hypoglycemic agents). Dyslipidemia was defined as total serum 
cholesterol >200 mg/dL or in treatment with statins and/or fibrates. Patients with intermittent 
claudication (IC) or with a history of lower limb revascularization (arterial bypass, angioplasty or 
stenting) were also considered as having PAD.
 2
 Asymptomatic PAD was defined as a resting ABI 
≤0,9 with an absence of prior lower-extremity peripheral vascular events or clinical symptoms 
indicative of intermittent claudication. Critical limb ischemia (CLI) was defined as limb pain that 
occurs at rest and that may be accompanied by tissue loss (ischemic ulcer or gangrene). Coronary 
artery disease (CAD) and Cerebrovascular disease (CVD) were assessed by clinical history 
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(myocardial infarction, stroke) or interventions. Patients with asymptomatic carotid stenosis were 
not classified as CVD. Height and weight were measured and body mass index was calculated as 
weight to height squared (kg/h²). The primary endpoint was total mortality (all-cause and 
cardiovascular mortality). 
Arterial stiffness and ABI measurement protocol 
 
Pharmacologic treatment was suspended (when possible) 12 hours before the measurements. 
Patients rested in a supine position for 5-10 minutes in a quiet room in a comfortable environment 
at a temperature of 22±1° C. The protocol of sequential measurements in the laboratory included: 
Brachial blood pressure measurement in the dominant arm using a standard mercury 
sphygmomanometer. Three readings were taken separated by 2-minute intervals, and the average 
was used for analysis. Peripheral pulse pressure (PP) was calculated as the difference between SBP 
and DBP. Arterial tonometry was performed using the SphygmoCor device (AtCor Medical, 
Sydney, Australia) in radial, carotid, and femoral arteries.
 14
 Radial pressure waveform was 
calibrated to brachial SBP and DBP measurements (obtained with the sphygmomanometer). The 
mean arterial pressure (MAP) was calculated integrating the calibrated radial pressure wave. 
Central pressure was determined using a transfer function from the radial artery pressure waveform.
 
15 
Augmentation pressure (AP) was defined as the difference between the second and the first 
systolic peak, of the derived aortic pressure waveform. The augmentation index (Aix) was defined 
as the difference between the second and first systolic peaks of the central arterial waveform, 
expressed as a percentage of the central pulse pressure. In addition, as Aix is influenced by heart 
rate, it was normalized for a standard heart rate of 75 bpm (Aix@75) in accordance with Wilkinson 
et al.
 16
 Aortic pulse wave velocity (aPWV) was measured by sequentially recording 
electrocardiography (ECG)-gated carotid and femoral artery waveforms. Wave transit time was 
calculated by software using the R wave of a simultaneously recorded ECG as a reference frame. 
The distance between the carotid and the femoral sampling sites was measured above the surface of 
the body with a tape. aPWV was determined by dividing the distance between the two recording 
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sites by the wave transit time. All measurements were made by one investigator (GS) in duplicate 
and mean values were used for the final analysis. Immediately after measurement of the arterial 
stiffness variables, the ankle systolic BP measurements for ABI calculation was obtained by two 
operators using an 8-MHz Doppler probe and a BP cuff after 10 minutes of rest with the patient in a 
supine position. The systolic pressure was measured on either the posterior tibial or dorsalis pedis 
artery. ABI was calculated by dividing the higher of the two ankle systolic blood pressures in each 
leg by the higher of the two brachial systolic blood pressures. The higher of the two brachial 
pressures was used as the denominator to account for the possibility of subclavian artery stenosis, 
which can decrease the blood pressure in the upper extremity. Peripheral arterial disease was 
defined as ABI ≤0,9 at rest or after Treadmill test performed on the borderline group (ABI=0.91-
0.99) to confirm PAD. The lowest ABI values were used for statistical analysis. 
 
Follow-Up 
Follow-up time was defined by the time from the baseline visit until the event date was censored at 
the last contact date. Information on events were obtained through follow-up visits, phone 
interviews and familial contacts. All deaths included in analysis were validated by research doctors 
who were unaware of the patient’s arterial stiffness tests using source data. Death as result of acute 
myocardial infarction, stroke, or heart failure was defined as a cardiovascular death. 
 
Statistical analysis 
Statistical analyses were performed using the statistical software JMP, version 10.0, SAS Institute 
Inc. 2012. Continuous variables were reported as mean ± SD, categorical variables as percentages 
for all patients. The statistical assessment of data was performed by Student t-test for numeric data 
and Pearson χ² for categorical data. Prognostic factors of mortality were identified by use of Cox 
proportional hazards regression model ABI, aPWV, Aix@75 were included as a continuous 
variables in the adjusted statistical model, along with the risk factors (age, sex, diabetes type 2, 
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dyslipidemia, hypertension, smoking history and CAD history). Survival curves were estimated by 
use of the Kaplan-Meier method and compared by using the Log-rank test. Variables were 
considered prognostic when they were found to be statistically significant (P<0.05). 
 
RESULTS 
Baseline characteristics 
The study group was composed of 398 subjects: 231 PAD patients and 167 No-PAD (Tables I). 
Referring to No-PAD, PAD patients showed a higher prevalence of common risk factors: 
hypertension (p<.0001), smoking history (p<.0001), type 2 diabetes mellitus (p=0.015) and CAD 
history (p=0.0016). In PAD patients the ABI was lower (p<.0001), SBP-brachial artery, PP-brachial 
artery aPWV and Aix@75 were higher (p<.0001), (p<.0001), (p=0.002); (p=0.010).  
71% of PAD patients were found to be asymptomatic Pharmacological treatment with anti-platelets, 
calcium-channel-blockers, ACE-I, β-blockers, ARBs, diuretics, statins and antidiabetics was 
significantly higher in PAD patients. 
 
All-cause and CV mortality in PAD and No-PAD groups  
During a mean follow-up of 5.4±2 years we observed 39 (16.9%) deaths of 231 PAD and 8 (4.8%,) 
of 167 No-PAD. Table 2 shows that when PAD and No-PAD groups were examined the age and 
aPWV was directly associated with total mortality (p=0.009) (p=<.0001) while ABI was inversely 
associated (p=0.018). In the analysis carried out in PAD patients alone the aPWV was directly 
associated with total mortality (p=0.011). Table 3 shows the results of a Cox multivariate regression 
model adjusted for multiple CV risk factors, (age, hypertension, diabetes type 2, smoking history, 
dyslipidemia) and previous CAD history. The aPWV, age and ABI were associated with a 
significant increase in total mortality risk: (p= 0.001), (p= 0.009) (p= 0.018) respectively, while Aix 
@75HR did not (p= 0.844). A separate analysis carried out in PAD patients showed that aPWV was 
associated with total mortality (p=0.016). In PAD and No-PAD total mortality was from all-cause 
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(77%-75%) while CV mortality (myocardial infarction, stroke) was respectively 23% - 25%.(Figure 
1). In both groups the most frequent cause of death was due to cancer (ie, lung, gastric, colon, 
leukemia/lymphoma and renal), followed by chronic obstructive pulmonary disease (COPD) and 
renal failure. 
Survival analysis for PAD and Non-PAD groups 
Figure 2 shows the survival distribution of the two ABI groups for total mortality. In particular, the 
Kaplan-Meier survival curves showed that the survival rate was lower in the PAD group (Log-rank 
p=0.0003). In PAD patients, (Figure 3) the survival in the third tertile of aPWV (≥11,5 m/s) is 
statistically lower (Log-rank test p=0.0005) with respect to the first tertile (≤9,3m/s). Table 4 shows 
that in PAD no-survivors with respect to survivors age and aPWV were higher (p=0.0001), 
(p<.0001) while the ABI and the use of cardiovascular drugs (antiplatelet, lipid-lowering, anti-
hypertensives) were comparable. 
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DISCUSSION  
In both sexes the presence of PAD is regarded as a marker of atherosclerosis in other vascular beds, 
and many epidemiological studies support the finding that PAD is a strong prospective predictor of 
all cause and cardiovascular mortality.
 4-7
 Our results have confirmed that these findings were also 
true for individuals referred to our vascular center for the evaluation of PAD. In particular, our 
analysis revealed that after further adjustment for potential confounders, a low (≤0.9) ABI value 
was strongly and inversely correlated with total mortality (Table 2) and the Kaplan-Meier survival 
curves showed that the survival rate was significantly lower in the PAD group compared with the 
normal ABI group (Figure 2). It has been hypothesized that increased PAD-associated mortality 
may be mediated by presence of systemic atherosclerosis that leads to arterial stiffening
 17
 thus the 
question addressed in this study was whether higher arterial stiffness is associated with total 
mortality (all cause and CV mortality). The results of the present study show that aPWV, considered 
the “gold standard” of arterial stiffness, but not Aix@75HR, is associated with total mortality in 
overall subjects. This predictive value of aPWV remained significant in PAD patients. 
independently of classic risk factors (hypertension, smoking history, type 2 diabetes, dyslipidemia) 
and CAD history often present in such patients. These observations are in accordance with the 
conclusions drawn in previous longitudinal studies, where the aPWV was proven to be an 
independent predictor of all-cause and cardiovascular mortality in the general population,
 18,19 
in 
patients with risk factors and conditions associated with PAD such as: type 2 diabetes,
 20 
hypertension
 21 
end-stage renal disease (ESRD).
 22
 To the best of our knowledge, only a recent study 
by Kals et al examined the predictive role of aPWV and Aix in PAD patients.
 12
 
The same Authors in a cohort of 117 men (aged 62,3±7,7 years) symptomatic PAD patients 
prospectively recruited between 2002 and 2010 reported 32 fatal events during the follow-up period 
(mean 4.1±2.2 years). In this study, decreased small artery elasticity was an independent predictor 
of all-cause and CVD mortality; in contrast aPWV and Aix were not. The reasons for this 
discrepancy in results are. not clear  however, we believe that the characteristics found in the 
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patients in the Kals et al study may explain the different results from our current study. In other 
words, the study by Kals et al had patients with a lower average ABI of 0.40 and of the 117 patients 
studied, 75 had stage II, 29 stage III, and 13 stage IV chronic ischemia as defined by Fontaine, 
while our study had an average ABI value of 0.68 and 71% were asymptomatic (stage I Fointaine), 
indicating a less severe population of PAD. It has been reported that in patients with severe PAD 
the aPWV measurement can result falsely low
 13,23
 and this could condition the predictive result of 
the aPWV. How the aortic stiffness is associated with a decreased survival rate in PAD patients did 
not readily identifiable in our study. However it is possible that the overlapping of common 
vascular risk factors (aging, smoking, diabetes, obesity, metabolic syndrome or insufficient physical 
activity) and the existence of common pathogenetic mechanisms (chronic inflammation, increased 
oxidative stress)
 24
 may contribute to aortic stiffening, atherosclerosis, and risk for the development 
of several malignancies (eg, lung cancer). 
25,26
 
 
 
Potential implications  
It has been widely documented that ABI has a prognostic role identifying patients with very high 
risk of mortality, independently of the presence or absence of symptoms. Compared to other 
diagnostic methods, ABI is superior because of its simplicity, being very easy to routinely 
determine in all patients and because it is a non-invasive test. Our observation that aPWV is 
associated with total mortality could have important implications. Compared to PAD survivors, 
PAD No-Survivors showed no differences in average ABI values (p=0.324) but a higher average 
aPWV (p=0.0001) (Table 4) and the Kaplan-Meier curves showed that survival in the third tertile of 
aPWV was significantly lower (Log-rank test p=0.0005) with respect to the first tertile (Figure 3). 
Therefore, aPWV measurement in a less severe population of PAD could be useful to stratify risk of 
mortality
 27,28
 in patients with known atherosclerotic disease. 
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Study limitations 
The present study must be interpreted within the context of its potential limitations. First, this study 
consisted of patients with mean age 68±8 years and less severe PAD, and thus the results may not 
apply to young PAD populations or to severe PAD patients.  
 
CONCLUSIONS 
This study provides further evidence in support of previous studies that have demonstrated an 
independent association between aPWV and mortality expanding understanding of the prognostic 
importance of arterial stiffness in atherosclerotic PAD patients. Even though it is very likely, further 
studies are required to confirm these results and to evaluate whether along with ABI, routine 
evaluation of aPWV could be helpful for risk stratification. 
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Figure 2. Kaplan-Meier survival curves from total mortality in the population study according to the level of 
ABI.Comparison between survival curves were statistically significant (Log-rank test (p=0.0003).  
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Figure 3. Kaplan-Meier survival curves from total mortality in the PAD according to the level of aPWV divided 
into teriles.Comparison between survival curves were statistically significant (Log-rank test (p=0.0005)  
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Table 1 - Clinical and demographic characteristic of study population 
Parameters 
Overall 
n°398 
PAD 
n°231 
No-PAD 
n°167 
p-value 
Age (years) - Mean (SD) 68±9 69±9 68±7 0.221 
Sex male, n % 294 (74) 169 (73) 125 (75) 0.704 
Height (cm) - Mean (SD) 164±9 164±9 165±9 0.234 
Weight (kg) - Mean (SD) 74±12 74±12 75±12 0.361 
BMI (kg/m
2
) - Mean (SD) 27±4 27±4 27±4 0.970 
Hypertension - n (%) 280 (70) 190 (82) 90 (54) <.0001 
Type 2 diabetes - n (%) 149 (37) 98 (42) 51 (31) 0.015 
Dyslipidaemia - n (%) 259 (65) 158 (68) 101 (60) 0.122 
Smoking history – n (%) 214 (54) 164 (71) 50 (30) <.0001 
CAD history - n (%) 96 (24) 69 (30) 27 (16) 0.0016 
CVD history - n (%) 16 (4) 12 (5) 4 (2) 0.160 
Anti-Platelets, n (%) 187 (47) 139 (60) 48 (29) <.0001 
Calcium-channel-blockers, n (%) 68 (17) 53 (23) 15 (9) 0.0007 
ACE-I, n (%) 91 (23) 68 (29) 23 (14) 0.0002 
β-blockers, n (%) 89 (21) 60 (26) 29 (17) 0.041 
ARBs, n (%) 82 (21) 60 (26) 22 (13) 0.001 
Diuretics, n (%) 34 (9) 26 (11) 8 (5) 0.022 
Statins, n (%) 130 (33) 96 (42) 34 (20) <.0001 
Antidiabetics, n (%) 98 (25) 68 (29) 30 (18) 0.008 
SBP - brachial artery (mmHg) 138±21 142±21 132±20 <.0001 
DBP - brachial artery (mmHg) 80±10 79±10 80±10 0.084  
PP - brachial artery (mmHg) 58±19 63±19 52±16 <.0001  
Mean Arterial Pressure (mmHg) 100±13 101±12 99±13 0.206  
Heart rate (bpm) 68±11 68±11 68±11 0.425  
Aix @75HR (%) 28±8 29±8 27±9 0.010  
aPWV 10,4±2,6 10,8±2,6 9,9±2,2 0.002 
Ankle Brachial Index 0,85±0,2 0,68±0,2 1,06±0,1 <.0001  
 
BMI: body mass index; CAD: coronary artery disease; CVD: cerebrovascular disease; ACE-I: 
Angiotensin-converting enzyme inhibitors; ARBs: Angiotensin II receptor blockers. SBP: Systolic 
Blood Pressure; DBP: Diastolic Blood Pressure, PP: Pulse Pressure; Aix @75HR: aortic 
augmentation index corrected for heart rate 75; c-fPWV: carotid-femoral Pulse Wave Velocity. 
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Table 2 - Multivariate regression analysis in overall subjects and PAD patients 
 Variables Estimate 95% CI P value 
Overall 
subjects 
aPWV (m/s) 0.160 0.065 - 0.252 <.0001 
Age 0.056 0.013 - 0.100 0.009 
ABI -1.673 -3.060 - 0.285 0.018 
Aix @75HR (%) -0.002 0.042 - 0.036 0.887 
PAD  
aPWV (m/s) 0.136 0.031 - 0.236 0.011 
Age 0.042 -0.001 - 0.089 0.061 
Aix @75HR (%) -0.016 -0.065 - 0.034 0.530 
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Table 3 - Hazards Ratio Analyses of  total mortality in overall subjects and PAD patients  
Variables Hazard Ratio 95 % CI  P value 
O
v
er
al
l 
su
b
je
ct
s 
aPWV 1.17 1.06 - 1.28 0.001 
Age 1.05 1.01 - 1.10 0.009 
ABI 0.18 0.04 - 0.75 0.018 
Aix@75HR 0.99 0.95 - 1.04 0.844 
P
A
D
 aPWV 
1.14 1.03 - 1.26  0.016 
Age 1.04 0.99 - 1.09  0.061 
Aix@75HR  0.98 0.93 - 1.03 0.530 
 
Adijusted for age, sex, hypertension, diabetes, dislypidemia, smoking history, CAD history. CI, 
confidence interval. 
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Table 4 - Clinical characteristic of Survivors and Non-survivors PAD patients 
Parameters 
Survivors 
(192) 
 
No-survivors 
(39) 
  
p-value 
Age (years) - Mean (SD) 68±10 73±6 0.0001 
aPWV 10,3±2,6 12,6±2,9 <.0001 
Ankle Brachial Index 0,69±0,2 0.66±0,2 0.324 
Aix @75HR (%) 29±8 28±6 0.528 
Sex male, n (%) 138 (72) 31 (79) 0.328 
BMI (kg/m
2
) - Mean (SD) 28±4 27±3 0.800 
Hypertension, n (%) 155 (81) 35 (90) 0.179 
Type 2 diabetes, n (%) 76 (40) 22 (56) 0.052 
Dyslipidaemia, n (%) 135 (70) 22 (56) 0.089 
Smoking history, n (%) 141 (73) 23 (59) 0.069  
CAD history, n (%) 56 (29) 13 (33) 0.064 
CVD history, n (%) 9 (5) 3 (8) 0.440 
Anti-Platelets, n (%) 121 (63) 18 (46) 0.049 
Lipid lowering therapy 82 (43) 14 (36) 0.431 
Anti - hypertensives therapy 134 (70) 25 (64) 0.484 
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